English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

The  CDKN2A  (cyclin dependent kinase inhibitor 2A/multiple tumor suppressor 1) gene, also known as the  P16  gene, encodes multiple tumor suppressor 1 ( MTS1 ), which belongs to the INK4 family. In tumor tissue,  CDKN2A  has a high expression level compared with normal tissue and reflects prognosis in tumor patients. Our research targeted the analysis of  CDKN2A  expression in 33 tumors and clinical parameters, patient prognosis and tumor immunity roles. The  CDKN2A  expression level was significantly correlated with the tumor mutation burden (TMB) in 10 tumors, and the expression of  CDKN2A  was also correlated with MSI (microsatellite instability) in 10 tumors.  CDKN2A  expression was associated with infiltrating lymphocyte (TIL) levels in 22 pancancers, thus suggesting that  CDKN2A  expression is associated with tumor immunity. Enrichment analysis indicated that  CDKN2A  expression was involved in natural killer cell-mediated cytotoxicity pathways, antigen processing and presentation, olfactory transduction pathways, and regulation of the autophagy pathway in multiple cancers.  CDKN2A  was significantly associated with several immune cell infiltrates in pantumors.  CDKN2A  may serve as a promising prognostic biomarker and is associated with immune infiltrates across cancers.

Comprehensive Analysis Revealed that CDKN2A is a Biomarker for Immune Infiltrates in Multiple Cancers